Law360, New York (November 20, 2008, 12:00 AM EST) -- In a blow to Johnson & Johnson, the European Union's drug-regulating body has recommended suspending approval for the sale of Ionsys in Europe because of a defect with the pain medicine's delivery system that could cause overdoses.
The European Medicines Agency's Committee for Medicinal Products for Human Use said Thursday it made the decision after J&J unit Janssen-Cilag International NV – which markets Ionsys in Europe – informed the CHMP that it had detected corrosion of a component of the system in one batch of the...
EU Calls For Suspension Of J&J's Ionsys
To view the full article, register now.
Try Law360 FREE for seven days
Already a subscriber? Click here to login
